StockTipsArenaBeta

BUY Dr. Lal Path Labs Ltd. — Morgan Stanley

BUYDr. Lal Path Labs Ltd.
Dr. Lal Path Labs share price target & all analyst calls

byMorgan StanleyHorizon: NA (inferred 1 year)27 Jul 2026via NDTV Profit

Entry₹1,827.2Inferred
Target₹1,960
Total upside +7.27% (call closed)
Stop lossNot given
Exit₹1,96010 Aug 2026, 12:08 pm
Target hit+7.27%0.00%upside left
Follow Morgan Stanley for new calls(97% target hit, 33 closed calls)Get alertsWatch LALPATHLAB for new buy/sell callsGet alertsSee 3 active Long-term calls on LALPATHLABSee 274 active Long-term picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

Frozen at close · 10 Aug 2026
11 supporting2 neutral0 opposing
Supports the BUY call (11)

Metropolis Healthcare: చిన్న పట్టణాల్లో దూసుకుపోతోంది.. లాభాల్లో **26%** వృద్ధి!

NewsGoogle News·6 Aug · 3d ago

(opens in new tab)

Metropolis Healthcare शेअरमध्ये तेजी! टियर-II/III शहरांमधील विस्ताराने नफा **26%** ने वाढला

NewsGoogle News·6 Aug · 3d ago

(opens in new tab)

2 advisors have active short-term BUY calls on this stock, all issued in the last 14 days

Advisor consensus · adjacent horizon·30 Jul · 1w ago

Dr Lal Path Labs shares soar 8% after Q1 earnings beat estimates. What Nomura, Nuvama, other brokerages are saying?

NewsEt-Markets·27 Jul · 2w ago

(opens in new tab)

Dr. Lal PathLabs reported Q1 FY27 results with revenue up 19.1% to Rs 798 Cr. EBITDA increased 28.7% to Rs 247 Cr. PAT was Rs 170 Cr. The company also announced an interim dividend of 50% (Rs 5/share)

BSE · Company Update·24 Jul · 2w ago

(opens in new tab)
Neutral / worth noting (2)

The Board of Directors approved un-audited financial results for Q1 FY27, declared an interim dividend of INR 5 per share, and approved the grant of stock options. Additionally, the company approved a

BSE · Company Update·24 Jul · 2w ago

(opens in new tab)
Weighs against the BUY call (0)

Nothing found in this tip’s window yet.

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Dr. Lal Path Labs

All analyst calls on Dr. Lal Path Labs

More from Morgan Stanley

Every call and its outcome